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Abstract We explore the impact of saturable distribution
over the central and the peripheral compartment in phar-
macokinetic models, whilst assuming that back flow into
the central compartiment is linear. Using simulations and
analytical methods we demonstrate characteristic tell-tale
differences in plasma concentration profiles of saturable
versus linear distribution models, which can serve as a
guide to their practical applicability. For two extreme
cases, relating to (i) the size of the peripheral compartment
with respect to the central compartment and (ii) the mag-
nitude of the back flow as related to direct elimination from
the central compartment, we derive explicit approxima-
tions which make it possible to give quantitative estimates
of parameters. In three appendices we give detailed
explanations of how these estimates are derived. They
demonstrate how singular perturbation methods can be
successfully employed to gain insight in the dynamics of
multi-compartment pharmacokinetic models. These
appendices are also intended to serve as an introductory
tutorial to these ideas.
Keywords Saturation  Distribution  Pharmacokinetics
Introduction
In practical applications, population pharmacokinetic
modellers are regularly confronted with data suggesting
nonlinear kinetics of the investigational compound. This
may include disproportionate increases in Cmax in single
ascending dose (SAD) data or disproportionate accumula-
tion in multiple ascending dose (MAD) data. Such non-
linearities may be difficult to account for using the standard
linear compartmental pharmacokinetic (PK) model, even
when nonlinear elimination is employed. Here we inves-
tigate a class of compartmental PK models which can be
characterized as saturable distribution models, which we
feel can provide an additional tool enabling pharmaco-
metric modelers to tackle observed nonlinearities in their
data.
Compartmental PK models usually combine a central or
plasma compartment, which represents the site at which
pharmacokinetic sampling takes place, with one or more
peripheral or tissue compartments. Such multi-compart-
mental models typically assume that drug enters the blood
stream in the central compartment, is distributed from there
via linear first order processes to the peripheral compart-
ments, and finally is eliminated again from the central
compartment via either a linear first order process or a
saturable Michaelis–Menten process (see e.g. Wagner et al.
[1] and more recently, Wu et al. [2], Brocks et al. [3] and
Scheerens et al. [4]). While linear distribution from central
to peripheral may often provide an adequate description of
the observed PK, very few processes in biology are truly
linear. Most, if not all biological processes are saturable
and may only appear linear because their maximum
capacity has not been approached in the observed data. It
follows that the standard multi-compartmental PK model
with linear distribution can be seen as a special case of a
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more general class of multi-compartmental PK models
with saturable distribution.
Snoeck et al. [5] first developed a population PK model
with saturable distribution to account for the nonlinear PK of
draflazine. This nonlinearity was found to be related to a
capacity-limited, high-affinity binding of draflazine to
nucleoside transporters located on erythrocytes and
endothelial tissue, and could not be accounted for by con-
ventional, linear distribution PK models. In the model
developed by Snoeck et al., draflazine was distributed from a
central compartment with linear elimination to three periph-
eral compartments, two of which were capacity-limited with
different capacities but similar affinity and were thought to
represent the specific binding of draflazine to its receptors on
erythrocytes and tissue, respectively. Thismodelwas found to
satisfactorily predict the nonlinear, dose-dependent PK of
draflazine and its disposition in whole blood and plasma.
In an unpublished study, the approach developed by
Snoeck et al. was used to model the PK of compound X,
which also showed a markedly nonlinear PK and was also
known to bind specifically to receptors on the erythrocytes.
Starting from a conventional three compartment PK
model, transformation of one of the two peripheral com-
partments to a low capacity, high affinity compartment
with saturable distribution resulted in a highly significant
improvement of the model fit. This compartment was
thought to represent specific binding to the receptors on the
erythrocytes, and addressed a nonlinear dose-dependent
increase of Cmax observable in single ascending dose
(SAD) studies. However, Fig. 1 shows that this 1-receptor
model still failed to address nonlinear dose-dependencies
in both accumulation and time to steady-state in multiple
ascending dose (MAD) studies. Transformation of the
second peripheral compartment to a very high capacity,
low affinity compartment with saturable distribution
addressed this problem and yielded a further, highly sig-
nificant improvement of the model fit. This 2-receptor
saturable distribution model was used to develop a suc-
cessful individual dose titration protocol, and was mathe-
matically analysed by Peletier et al. [6].
What kind of non-linearities in the observed PK can be
addressed by saturable distribution models, when and how
should we apply them? In the following we address such
questions by exploring the dynamics of a two-compartmental
model with a saturable, Michaelis–Menten type rate function
for the distribution of drug from the central to the peripheral
compartment. We do this for two opposing variants of sat-
urable distribution: first, we explore the dynamics of a model
with a low affinity, high capacity distribution process, and
then discuss the dynamics of a model with high affinity, low
capacity distribution. In order to assess the impact of satura-
tion, we analyse the dynamics of two classes of models: one
with linear and one with saturable distribution.
The objectives of this paper are
(i) To identify characteristic properties of the time
courses in the central compartment, and identify
differences between linear and saturable models
which may serve as handles to determine which
class of models should be used to fit a given set of
data.
(ii) To study the dynamics of the nonlinear model
incorporating saturation with a view to understand
the impact of the relative capacities and the rate
constants of the system and identify the charac-
teristic time-scales.
(iii) To identify the impact of saturable distribution in
practical applications, such as the exposure result-
ing from SAD and MAD regimens.
The mathematical analysis that is used to prove the results
in this paper is presented in three appendices. The first two
are devoted to the large capacity case, the linear model and
the saturable model, and the third appendix is devoted to
the small capacity case. The analysis relies strongly on
applications of singular perturbation theory (cf. [7, 8]). The
appendices are written so that they can be used as a tutorial
for applications of this method in pharmacokinetics and
pharmacodynamics.
Methods
In order to study the impact of saturation we compare the
dynamics of two distribution models, one with linear and
one with nonlinear distribution that involves saturation. In
Fig. 1 Individual plasma concentration versus time profiles for six
subjects receiving a once-daily oral 1500 mg over a period of
3 weeks. The cyan dots show the observed plasma concentrations, the
black curve shows the individual fit and the grey curve the population
fit of the 2-receptor model, while the magenta curves show the
individual fits of the 1-receptor model
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both models a test compound or drug is supplied to an
absorption space (1). The drug is then discharged into a
central compartment (2), distributed over a peripheral
compartment (3), as well as eliminated from the central
compartment.
Linear distribution model
This is the standard linear two-compartment distribution
model in which drug flows between the central compart-
ment (1) and the peripheral compartment by diffusion in
which the flux is proportional to the difference of the
concentrations in the two compartments.
The amount of drug in the absorption space is denoted
by A1 and the concentrations in the central and the
peripheral compartment are denoted by, respectively, C2





















Here q denotes the infusion rate, ka a first order rate con-
stant, Cl the non-specific clearance, Cld the intercompart-
mental distribution and V2 and V3 the volumes of the
central- and the peripheral compartment.
In comparing this linear distributionmodel to the nonlinear
model involving saturation below, it is convenient to use the
amount of drug in the central compartment (A2 ¼ V2  C2)
and in the peripheral compartment (A3 ¼ V3  C3). Intro-
ducing these amounts into the system (1) then results in the






¼ kaA1  k20A2  H  kpA2 þ kpA3
dA3
dt












; kp ¼ Cld
V3
and H ¼ V3
V2
and H is a dimensionless constant which can be viewed as a
measure of the ‘‘relative capacity’’ of the central and the
peripheral compartment.
Nonlinear or saturable distribution model
In this model the transfer from the central compartment to
the peripheral compartment is saturable, whilst that from
the peripheral back to the central compartment is linear.






¼ kaA1  k20A2  Bmaxkp A2













where q; ka; k20 and kp are as in the linear problem. Here
Bmax is referred to as the capacity of the peripheral com-
partment and KM the Michaelis–Menten constant. Both
Bmax and KM have the dimension of an amount. Thus,
saturation is modelled by a Michaelis–Menten term which
involves two new parameters, the capacity Bmax and KM .
This model has five parameters whereas the linear model
has four.
Remark For values of A2 which are small relative to KM ,
the Michaelis–Menten term in the nonlinear system may be
approximated by ðBmax=KMÞkpA2. Thus the relative
capacity H in the linear system may be compared to the
quotient Bmax=KM in the nonlinear system.
In the large capacity case, the infusion rate q is assumed
to be constant, and initially the system is assumed to be
empty, i.e., the amounts in the compartments are all
assumed to be zero:
A1ð0Þ ¼ 0; A2ð0Þ ¼ 0 and A3ð0Þ ¼ 0 ð4Þ
In the small capacity case, the infusion rate q is assumed to
be zero, and the initial conditions after an iv dose D are
given by
A1ð0Þ ¼ D; A2ð0Þ ¼ 0 and A3ð0Þ ¼ 0 ð5Þ
Steady state
For reference we give here the steady state values of A1;A2
and A3 when A1 is supplied to the absorption space at a
constant rate kf ðtÞ  q. Equating the temporal derivatives
in Eqs. (2) and (3) to zero we obtain the following
expressions for the steady state amounts Ai;ss (i ¼ 1; 2; 3):
A1;ss ¼ q
ka
; A2;ss ¼ q
k20




; A2;ss ¼ q
k20
; A3;ss ¼ Bmax q
qþ KM  k20
ð6Þ
Thus, we can write A3;ss in terms of A2;ss:
A3;ss ¼ H  A2;ss ðLinearÞ and
A3;ss ¼ Bmax A2;ss
A2;ss þ KM ðNonlinearÞ
ð7Þ
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We conclude that in both models A1;ss and A2;ss are the
same and increase linearly with the infusion rate q. In the
linear model the amount A3;ss in the peripheral compart-
ment also increases linearly with q, but in the nonlinear
model it increases nonlinearly and converges to the
capacity Bmax as the infusion rate tends to infinity:
lim
q!1A3;ss ¼ Bmax ð8Þ
We shall see however that whereas in the linear model the
time needed for A2ðtÞ to reach steady state is independent
of q, in the nonlinear model it varies with the infusion rate.
Evidently, in the absence of an infusion rate, i.e., when
q ¼ 0, the steady state is given by ðA1;A2;A3Þ ¼ ð0; 0; 0Þ.
We contrast the dynamics of models with large capacity
peripheral compartment, combined with slow transfer with
models with small capacity peripheral compartments
endowed with rapid transfer.
Large capacity and slow distribution
We assume,
A.1 The capacity of the peripheral compartment is large
compared to that of the central compartment.
A.2 The drug flows back from the peripheral compart-
ment into the central compartment at a much smaller rate
than it is eliminated from the central compartment.
Specifically, in terms of the rate constants we assume that:
ka  k20  kp ð9Þ
Small capacity and rapid distribution
We assume,
A.3 The capacity of the peripheral compartment is small
compared to that of the central compartment.
A.4 Elimination from the central compartment is much
slower than the rate with which the drug flows back into the
central compartment.
ka  kp  k20 ð10Þ
Simulations
In order to acquire a qualitative understanding of the
structure of the dynamics of both models, given the relative
magnitudes of the rate constants ka, k20 and kp, and the
capacity of the peripheral compartment of the linear model
(H) and the nonlinear model (Bmax), we perform a series of
simulations. We do this separately for the large and the
small capacity peripheral compartment.
Large capacity and slow distribution
We select a series of different values of the infusion rate
q in order to demonstrate the differences between the linear
and the nonlinear model. These simulations will then be
done for the following parameter values:
Because of the large value of ka, the compound in the
absorption space very quickly reaches a quasi-steady state so
that we may put A1ðtÞ ¼ A1;ss ¼ q=ka for t[ 0. Thus, the
dynamics of the system is effectively determined by the inter-
action between the central and the peripheral compartment.
In Figs. 2 and 3 we show how in the linear and the
nonlinear model the amount of compound in the central
compartment (A2) evolves with time for the different
infusion rates. The simulations for the linear and the non-
linear system look similar. Both exhibit a clear two-phase
structure, which can be divided into:
A brief initial phase in which A2 climbs to what appears
to be a plateau. We shall refer to this value of the amount of
compound as the Plateau value and denote it by A2.
Fig. 2 Linear model (2) graphs
of A2ðtÞ for increasing infusion
rates q ¼ 1, 2, 3, 4, 5 mg h1
when ka ¼ 10, k20 ¼ 102, kp ¼
104 h1 and H ¼ 100
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 A second, much longer phase in which the final pla-
teau value A2 of the first phase serves as a starting point of
a slow rise towards the final limit which, as expected, is the
steady-state value A2;ss.
However, Figs. 2 and 3 demonstrate that the impact of
the infusion rate q is very different. Here we focus on how
the infusion rate q affects the following characteristics of
the dynamics:
(1) The plateau value A2 after the first phase.
(2) The half-life of the convergence to the plateau value
A2 as well as the half-life of the convergence to the
final steady state value A2;ss.
As can be expected from a linear problem,we see in Fig. 2 and
Eq. (6) that A2 and A2;ss depend linearly on q and that the half
lives in the twophases are independentof the infusion rate.The
simulations in Fig. 3 demonstrate that for the nonlinear model
the influence of the infusion rate q is more complex. However,
the terminal stateA2;ss is the same as for the linear problem (cf.




Thus, in comparing the two models one needs to focus on
the complete temporal profile i.e., the concentration versus
time profile for all time. We make the following
observations:
• The plateau value, A2, increases with increasing q. For
the linear model A2 is seen to increase linearly with q
(cf. Fig. 2) whilst for the nonlinear model the depen-
dence on q appears to be super-linear, i.e., A2 appears
to grow faster than linearly with q (cf. Fig. 3).
• The half-life in the two phases. As the infusion rate
q increases, the half-life in the first phase appears to
increase whilst the half-life in the second phase appears
to decrease.
Small capacity and rapid distribution
In Fig. 4 we present a series of simulations for nonlinear,
saturable distribution model which exhibit the impact of an
iv bolus dose on the initial peak of A2ðtÞ. The doses and the
parameter values are given in Table 2 in Appendix 2:
Fig. 3 Nonlinear model (3)
graphs of A2 versus time for the
parameter values ka ¼ 10,
k20 ¼ 102, kp ¼ 104 h1,
Bmax ¼ 3 104 mg, KM ¼ 102
mg
Fig. 4 Nonlinear model (3)
graphs of A2 versus time for
D0 ¼ 10; 20; . . .; 70 for the
parameter values ka ¼ 5, k20 ¼
0:2 h1, kp ¼ 1 h1, Bmax ¼ 100
mg, KM ¼ 10 mg
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It is seen that in this case the disposition also has a two-
phase structure: soon after administration, A2ðtÞ jumps up
to a high Peak value A2;max quickly drops thereafter (left
figure) and then, in a second phase slowly returns to zero
(right figure). This Peak value is seen to increase rapidly
with D in a super-linear manner: when D increases from 10
to 20 mg then A2;max rises by about 4 mg and when D in-
creases from 60 to 70 the rise is about 7 mg, i.e., almost
double the low-dose increase.
Thus, as in the large capacity case, the graphs of A2
versus time exhibit a two-phase structure, albeit with a
completely different shape. A brief initial phase, say for
0\t\t0, in which A2ðtÞ exhibits a violent up- and down
swing which ends with A2 at an intermediate plateau value
A2, followed by a much longer elimination phase.
Results
Many of the observations made in the simulations can be
explained through mathematical analysis of the linear two-
compartment model (2) and the nonlinear model (3). Below
we present a series of results from such analysis. We discuss
the large capacity and the small capacity case in succession.
Large capacity and slow distribution
At first sight the simulations in Figs. 2 and 3 for the two
models are qualitatively similar: a rapid rise of A2 towards
an intermediate plateau A2, the plateau value, followed by
a slow rise towards the final steady state A2;ss given in
Eq. (6). In order to discriminate between the dynamics of
the linear and the nonlinear model it is therefore important
to obtain detailed and quantitative information about
characteristics of the dynamics over time. We focus here
on two such characteristic properties:
– The intermediate plateau value A2, and
– The half-life of the convergence as A2 tends to A2, and
as A2 tends to A2;ss
and the way these quantities depend on the infusion rate,
the capacity and the different rate constants.
For both models we present such quantitative estimates
of the plateau value and the half-life in the first and the
second phase. Their proofs are given in the mathematical
analysis presented in Appendices 1 and 2.
Plateau value
The existence of a plateau value is a result of the two-phase
structure of the dynamics of this system in which two
different time scales can be distinguished:1
Short : t1=2 ¼ Oð1=k20Þ k20 !1 and
Large : t1=2 ¼ Oð1=kpÞ kp ! 04
ð12Þ
In light of the basic assumption (9) there is a significant
difference between these two time scales. For the param-
eter values of Table 1 the half-life of the first phase is about
a factor 100 shorter than that of the second phase.
During the first phase, return flow from the peripheral
compartment is still negligible because kp is very small and
A3 is still building up. Therefore, during this phase the term
kpA3 modelling the back flow from the peripheral com-
partment into the central compartment may be omitted.
Removing this term from the equation for A2 in the systems
(2) and (3) yields a single differential equation involving
A2 only.
– Linear model: In the absence of back flow from the
peripheral compartment, the amount of compound in the
central compartment is governed by the equation
dA2
dt
¼ q k20A2  H  kpA2 ð13Þ
In this equation the input term kaA1 has been replaced by
the infusion rate q because, thanks to the large value of ka,
within a very short time we have kaA1ðtÞ  q.
The right hand side of Eq. (13) has a unique zero, the
plateau value A2, and it can be shown that
A2ðtÞ ! A2 ¼ q
k20 þ H  kp as t!1 ð14Þ
Table 1 Parameters values for the linear and the nonlinear model, (2) and (3)
Model ka k20 kp H Bmax KM q
Linear 10 0.01 0.0001 100 – – 1, 2, 3, 4, 5
Nonlinear 10 0.01 0.0001 – 3 104 100 1, 2, 3, 4, 5
h1 h1 h1 – mg mg mg h1
1 The big O-symbol compares the growth of a function, say f(x), as
x! 0 or x!1 to that of a simple function, say g(x). Often
gðxÞ ¼ xp, where p may be positive or negative. Specifically: f ðxÞ ¼
OðgðxÞÞ as x! 0 ð1Þ if there exist a constant M such that
jf ðxÞj 	MjgðxÞj for x small (large)








i.e., the plateau value is smaller than the steady state value.
Thus, the plateau value can be seen as the starting value of
the second phase in which A2ðtÞ climbs further towards the
final value A2;ss.
Remark Because the system (2) is linear, the amounts
A1;A2 and A3 will depend linearly on the infusion rate q.




 A2 ¼ 1
k20 þ H  kp ¼ Constant ð16Þ
– Nonlinear model: Without back-flow from the peripheral
compartment, the dynamics in the central compartment is
now governed by the equation
dA2
dt
¼ q k20A2  Bmaxkp A2
KM þ A2 ð17Þ
and
A2ðtÞ ! A2 as t!1 ð18Þ
where A2 is the unique positive zero of the right hand side

















q k20 KM  kp Bmax




In Fig. 5 we show how in the nonlinear model, the plateau
value A2 and the plateau value normalised with respect to
the infusion rate A2=q vary with q.
In contrast to the linear model, where this quotient is
constant, in the nonlinear problem the normalised plateau
is seen to be an increasing function of q, which connects
two asymptotes. Expanding the expression for A2=q in (19)















 reflect the fact that
(1) For large values of A2, i.e., A2  KM , the saturable
nonlinear term is small compared to the linear term
k20  A2 (Bmax  0) and the model approximates a
linear model with H ¼ 0.
(2) For small values of A2 (A2  KM), the nonlinear
Michaelis–Menten term may be approximated by a
linear term: kpðBmax=KMÞ  A2 and the model
approximates a linear model with H ¼ ðBmax=KMÞ.
The limit obtained in (21) then corresponds with
what is seen for the linear model in (14).
(3) For any fixed q[ 0, the plateau value A2 decreases








(4) The small infusion limit in Eq. (21) demonstrates the
sensitivity of the plateau value to changes in Bmax.
Conclusion
The simulations shown in Fig. 5, together with the analytical
estimates derived from the model equations provide valuable
Fig. 5 Variation of the plateau
value A2ðqÞ (left) and the
normalised plateau value
A2ðqÞ=q (right) for the nonlinear
model as they vary with q, when
the data are kp ¼ 104 h1,
k20 ¼ 102 h1, the capacity
takes the values: Bmax ¼ 104
(blue) 3 104 (red) and 6 104
(green) mg, and KM ¼ 100 mg
2 We write f ðxÞ L gðxÞ as x!1 when limx!1ff ðxÞ=gðxÞg ¼ L.
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diagnostic tools for identifying saturable elimination.
Increasing the infusion rate we observe (i) An increasing
plateau value which, when normalised by the infusion rate q,
is still increasing and is uniformly bounded above and below
by positive limits ‘
. (ii) Simple explicit expressions for ‘

which yield quantitative information about k20 and
kpBmax=KM . (iii) Additional estimates forBmax,KM and kp can
be obtained from the value of q at the transition from ‘ to ‘þ.
Terminal slope
In both models, the amount of compound A2ðtÞ in the central
compartment converges, in the first phase towards the pla-
teau valueA2 and then in the second phase towards the steady
state A2;ss. The rate of convergence towards these limits is
characterised by the half-life (t1=2) or the terminal slope kz.
We obtain accurate approximations for the terminal slope for
each of themodels,whichwe denote by kð1Þz for the first phase





vary with the infusion rate q and the capacity H or Bmax: –
Linear model in this model the terminal slope is independent
of the infusion rate. We obtain












Thus, as the capacity H increases, the terminal slope
changes in opposite directions: in the first phase it increases
and in the second phase it decreases, i.e.,
kð1Þz ðHÞ % and kð2Þz ðHÞ & as H % ð24Þ
– Nonlinear model: We present the terminal slope in the
first phase and in the second phase in succession
For the first phase we establish that:
kð1Þz ðq;BmaxÞ ¼ k20 þ Bmax kp
KM
fKM þ A2ðq;BmaxÞg2 ð25Þ
where A2ðq;BmaxÞ is the plateau value. We deduce the
following properties:
(1) As we have seen in Fig. 5, the plateau value A2
increases when the infusion rate q increases. Hence,
it follows from (25) that kzðq;BmaxÞ is a decreasing
function of q.
(2) When q!1, then A2ðq;BmaxÞ ! 1 and hence, by
(25),
kð1Þz ðq;BmaxÞ ! k20 as q!1 ð26Þ
(3) When q! 0, then A2ðq;BmaxÞ ! 0 and hence, by
(25),
kð1Þz ðq;BmaxÞ ! k20 þ
Bmax
KM
kp as q! 0
ð27Þ
(4) The terminal slope in the first phase kð1Þz ðq;BmaxÞ
increases as Bmax increases. To see this note that
according to Fig. 5, the plateau value A2ðq;BmaxÞ
decreases when the capacity Bmax increases.
For the Second phase the terminal slope is well approxi-
mated by the formula





The right hand side suggests the following properties:
(1) kð2Þz ðq;BmaxÞ is an increasing function of q and a
decreasing function of Bmax.
(2) By expanding the expression for kð2Þz ðq;BmaxÞ in (28)















Note that as q! 0, the terminal slope kð2Þz ðq;BmaxÞ of the
nonlinear model approaches that of the linear problem
given by (23) with H ¼ Bmax=KM .
Figure 6 illustrates and confirms the analytical properties
presented above. For the linear model they will be proved in
Appendix 1 and for the nonlinear model in Appendix 2.
Conclusion
The simulations displayed in Fig. 6, together with analyt-
ical expressions for the dependence on q of the terminal
slope in the first and the second phase are a rich source of
information for estimating the different parameters in the
models. For both phases, the terminal slope depends
monotonically—first down and then up—on q and tends to
finite non-zero limits as q! 0 and q!1 which can be
computed explicitly.
Impact of slow leakage from the peripheral
compartment
In many practical situations, data are only available for the
first phase, and only predictions can be made about the
second phase [6]. Clearly, during the long second phase,
with its slow dynamics, the influence of leakage from the
peripheral compartment may well be relevant. In light of
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the large capacity of the peripheral compartment this may
result in significant losses.
In order to assess the impact of leakage, we modify the
nonlinear model and increase the first order loss term in the
equation for the peripheral compartment by a factor
ð1þ aÞ, where a[ 1. The equation for A3 in the nonlinear




KM þ A2  ð1þ aÞ kp A3 ð30Þ
whilst the equation for A2, which does not involve a,
remains the same.
Because it is assumed that kp  k20, the two-phase
structure is not affected by moderate leakage. And because
during the first phase the elimination term in the equation
for A3 is small and may be neglected, the first phase will
hardly change when some leakage takes place from the
peripheral compartment.
On the other hand, during the second phase the impact
of leakage will be felt. For instance, leakage has an impact
on the steady state values of A2 and A3. They now become:















 q ¼ 0
ð32Þ
Note that this equation is the same as Eq. (19) for the
plateau value A2, except for the factor a=ð1þ aÞ which










Thus, when there is little leakage ða 1Þ, then A2;ssðaÞ is
close to the steady state value A2;ss given by (6) and when
leakage is substantial ða 1Þ, the steady state value drops
down to the plateau value A2 given by (20).
In Fig. 7 we show how the temporal behaviour of A2
changes as the elimination from the peripheral compart-
ment increases beyond the original back-flow into the
central compartment. The rate of infusion is kept constant
(q ¼ 5) and the elimination is increased from the original
value (a ¼ 0) in four steps to a ¼ 0:5; 1; 2 and 4.
The simulations confirm the analysis: the two-phase
structure remains intact, and in the first phase (Fig. 7 left
panel) the the additional elimination does not show up in
Fig. 6 Terminal slopes:
kð1Þz ðq;BmaxÞ (left) in the first
phase and kð2Þz ðq;BmaxÞ (right)
in the second phase versus the
infusion rate q for the nonlinear
model for two values of the
capacity: Bmax ¼ 104 (red) and
Bmax ¼ 3 104 mg (blue) and
the rate constants ka ¼ 10,
k20 ¼ 102, kp ¼ 104 h1, and
KM ¼ 102 mg
Fig. 7 Nonlinear model with
leakage from the peripheral
compartment (3) & (30). Graphs
of A2 versus time for q ¼ 5 and
a ¼ 0; 0:5; 1; 2; 4 for the
parameter values ka ¼ 10 h1,
k20 ¼ 0:01 h1, kp ¼ 104 h1,
Bmax ¼ 3 104 mg, KM ¼ 102
mg
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the graphs. In the second phase (right panel) elimination
does have an impact, and shows a drop in final steady state,
starting from the original value (a ¼ 0) and approaching a
value close to the plateau value when a ¼ 4.
Evidently, the half-life in the second phase decreases as
elimination from the peripheral compartment increases.
Conclusion
Elimination is a long-term phenomenon, as is to be
expected since it takes place from the peripheral com-
partment which fills up slowly since kp is small.
Nonetheless, the impact on the central compartment can be
significant and, even for moderate elimination rates, can
obliterate most of the growth beyond the first phase.
Small capacity and rapid distribution
To fully appreciate the effect of a large capacity of the
peripheral compartment combined with a slow exchange
between the two compartments, we conclude with a brief
discussion of the dynamics of the nonlinear model for the
converse situation: small capacity of the peripheral com-
partment combined with a fast exchange between the two
compartments. Thus, we here assume that
ka  kp  k20 ð34Þ
Since in this case the peripheral compartment has small
capacity and direct elimination is relatively small, one
expects that an iv bolus administration will lead to a large
peak in concentration in the central compartment. In
practical situations the height of this peak can be critical.
Thus, to gain insight into this feature we focus here on
dynamics after an iv bolus dose.
As expected, soon after administration, A2ðtÞ jumps up
to a high peak value A2;max. This peak value is seen to
increase rapidly with D0 in a super-linear manner: when
D0 increases from 10 to 20 mg then A2;max rises by about 4
mg and when D0 increases from 60 to 70 the rise is about 7
mg, i.e., almost double the low-dose increase.
Thus, as in the large capacity case, the graphs of A2
versus time exhibit a two-phase structure, albeit with a
completely different shape. A brief initial phase, say for
0\t\t0, in which A2ðtÞ exhibits a violent up- and down
swing which ends with A2 at an intermediate plateau value
A2, followed by a much longer elimination phase.
In order to analyse the dynamics of this system for the
parameer values constrained by the conditions (34) and
obtain an estimate for A2;max it is necessary to transform the
system to dimensionless variables. This analysis, carried out
in Appendix 3, yields the following estimates for A2;max.
A2;maxðDÞ
MM=ðM1Þ  D asD! 0












Because the initial phase is short and the elimination rate
k20 is small, the total amount of drug in both compartments
is conserved during this initial phase. i.e.,
A2 þ A3 ¼ D for 0	 t	 t0 ð36Þ
Because of the larger value of kp the two compartments are
quickly in quasi-steady state, so that after a brief initial
adjustment, we may put
A3 ¼ uðA2Þ ¼def Bmax A2
KM þ A2 for t t0 ð37Þ
Because Eqs. (36) and (37) both hold at t0, we may use
Eq. (36) to eliminate A3 from Eq. (37) to obtain
A2 þ Bmax A2
KM þ A2
¼ D ð38Þ
from which we can compute the value of A2, right after the




1þ ðBmax=KMÞ as D! 0





which clearly demonstrates the super-linear behaviour of


















In order to determine the long time behaviour of A2ðtÞ, we




ðA2 þ A3Þ ¼ k20 A2 ð41Þ
because q ¼ 0. We now use the expression for A3 given by
Eq. (37), which is valid in the second phase to eliminate A3
from Eq. (41) to obtain
d
dt
A2 þ uðA2Þf g ¼ k20 A2 for t[ t0
Using the expression for uðA2Þ this equation can be written
as






0ðA2;ssÞ ¼ Bmax KMðKM þA2Þ2
ð42Þ
where u0ðA2Þ denotes the derivative of the function uðA2Þ.
The terminal slope kð2Þz of the graph of A2 as it approaches




Since u0ðA2Þ is a decreasing function of A2 it follows that
the terminal slope increases as A2;ss increases, i.e, as D
increases. In particular, since u0ðA2Þ ! Bmax=KM as
A2 ! 0, it follows that
kð2Þz ðD;BmaxÞ !
k20
1þ ðBmax=KMÞ as D! 0 ð44Þ
so that t1=2 ! f1þ ðBmax=KMÞg lnð2Þ=k20  38 h for the
parameter values used in Fig. 4. We see that this estimate is
confirmed in Fig. 4.
Conclusion
We find that for small capacity and rapid exchange
between central and peripheral compartment the dynamics
has a brief initial phase followed by a long terminal phase,
with an appropriately defined plateau value in between. As
in the previous case the terminal slopes yield sensitive
markers that can be used to identify the impact of satura-
tion on drug distribution. The plateau value informs about
the capacity Bmax and KM , whilst the terminals slope yields
estimates for Bmax, KM , and about ka when
ðBmax=KMÞ kp[ ka and about kp when ðBmax=KMÞ kp\ka.
Discussion
We have compared the dynamics of two types of models for
the distribution of a compound over a central and a
peripheral compartment. In one type the elimination of
compound from the central compartment into the peripheral
compartment is linear, and the other it is saturable and hence
nonlinear. In both models, the return flow from the periph-
eral compartment to the central compartment is linear.
We have focussed on two contrasting extreme cases:
(i) In one case, the capacity of the peripheral compartment
is large and the back-flow is slow, and (ii) In the other case
capacity and back-flow are respectively, small and fast.
These cases can be viewed as bench marks in parameter
space since they exhibit very different dynamics, each
being endowed with its own characteristic ligand versus
time graphs.
Both types of graphs exhibit a two-phase structure.
However, within these two phases each case has its own
characteristic behaviour: the large capacity peripheral
compartment retaining ligand for a long time, whilst in the
small capacity compartment the presence of ligand, though
large, is short-lived.
It is demonstrated that saturable distribution can lead to
disproportionately higher steady-state exposures.
Specifically:
• In the large capacity/slow distribution case, multiple
ascending doses (MAD) yield disproportionately higher
steady state exposures.
• In the small capacity/fast distribution case, SAD yield
disproportionately higher Cmax.
Thus saturable distribution models merit a careful analysis
in light of the impact saturation may have on exposure.
In analysing these models subject to the conditions (46–
49) listed in Methods, a mathematical framework has been
created which can be used to analyse comparable models,
which involve additional processes such as (i) leakage, or
(ii) binding of the ligand to proteins, lipids and receptors in
the central or the peripheral compartment, such as dis-
cussed in [9], or (iii) when the model involves additional
compartments. This analytical machinery makes it possible
to give quantitative estimates of the impact of these pro-
cesses on the drug distribution between compartments and
over time.
As an application of the methods developed in this
paper, we show that leakage from the peripheral com-
partment may have considerable impact over a period of
time. If this period extends beyond the period over which
measurements are available the need for accurate quanti-
tive predictions is evident.
Distribution over two compartments in which the
peripheral compartment has a limited capacity, has much in
common with tissue-binding. Here it is the tissue, viewed as
a separate compartment, which can become saturated when
maximal occupancy is reached. Thanks to this similarity in
structure many of the results established in this paper can
easily be transposed to the dynamics of tissue-binding.
The mathematical analysis is presented in a series of
appendices. They offer an introduction to the use of such
methods as (i) the use of dimensionless variables and
parameters and (ii) multi-scale analysis. Dimensionless
parameters are often a numerical measure of the relative
importance of different processes involved in the model,
such as direct elimination from the central compartment
and distributional transfer between the compartments.
Different time-scales are a common occurrence in phar-
macokinetics and pharmacodynamics, often due to large
differences in concentrations, in rate constants or in bind-
ing constants. They make it possible to simplify the often
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complex systems by means of singular perturbation theory
(cf. [7, 8]). The appendices demonstrate the practical use-
fulness of this theory for the study of complex pharma-
cokinetic and pharmacodynamic systems, and can serve as
an introductory tutorial.
In summary, we have demonstrated a number of inter-
esting dynamic properties of saturable distribution models
which can be of value in practical modelling applications.
In particular, we have shown that such models can account
for disproportional accumulation evident in MAD data as
well as disproportional increase in Cmax in SAD data. This
is achieved by relaxing the assumption of linear distribu-
tion in the standard model at the cost of only one extra
parameter per peripheral compartment. Saturable distribu-
tion models share many properties with models for tissue
and receptor binding, which provides another attractive
mechanistic underpinning for this class of models. For
these reasons, we feel that the saturable distribution model
deserves a more prominent place in the pharmacometri-
cian’s toolbox than it currently has. Here we try to promote
this by providing a guide to its dynamics and, hence,
applicability.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
Appendixes
Appendix 1: mathematical analysis of the linear
problem
In Appendices 1 and 2 we focus on the large capacity -
slow distribution case (cf. 46 and 47). Thus,
ka  k20  kp ð45Þ
and initially Aið0Þ ¼ 0 for i ¼ 1; 2; 3.
In order to compare the ‘‘weight’’ of different terms in
the system (2) we introduce dimensionless variables. Thus,
we use the steady state values as reference value and put
x ¼ A1
A1;ss
; y ¼ A2
A2;ss
; z ¼ A3
A3;ss
ð46Þ
where A1;ss, A2;ss and A3;ss are given by (6). Introducing


















This is a linear system, so that on any bounded time
interval the solution is bounded.
It remains to introduce a dimensionless time variable. For
this purpose we choose three different time scales, each
corresponding to one of the rate constants in the system (47).
A very short time scale
We choose k1a h as a reference time and define the
dimensionless time s0 ¼ ka t. Introducing this time variable





















By assumption (9) the parameters m and e are small. For the
parameter values of Table 1 for the linear problem which
are used in Fig. 2, they are: e ¼ 103 and m ¼ 102.
It follows that given any finite time interval 0	 s0\T0,
then as m! 0, the solution of the system (48) converges


















Remembering that initially, ðx; y; zÞ ¼ ð0; 0; 0Þ, it follows
that for 0	 s0	 T0, the solution of the original system (48)
is well approximated by
xðs0Þ ¼ 1 es0 ; yðs0Þ ¼ 0; and zðs0Þ ¼ 0
ð50Þ
Evidently, xðs0Þ ! 1 as s0 !1. The half-life s0;1=2 - i.e.,
the time it takes for xðs0Þ to reach half of its final value, is
equal to lnð2Þ. Thus, in the original time variable t, the
half-life is given by t1=2 ¼ lnð2Þ=ka ¼ 0:07 h, which
amounts to about 4 min.
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A short time scale
We choose 1=k20 h as a reference time and define the
dimensionless time s1 ¼ k20 t. Introducing this new time












Using phase-plane arguments (cf. [11]) it can be shown that
0\yðs1Þ\1 for all s1[ 0. Therefore, 0\zðs1Þ\e for all
s1[ 0 and hence, since e 1, we may put zðs1Þ ¼ 0, and
approximate the first equation of (50) by
dy
ds1
¼ 1 ð1þ e HÞ y ð52Þ
where we have retained the product e H, because it may
not be small. The steady state value in this first phase is
y ¼ ð1þ e HÞ1; it is the plateau value y. It follows that
yðs1Þ ! y ¼ 1
1þ e H as s1 !1 ð53Þ
and the half-life s1;1=2 in this initial phase are given by
s1;1=2 ¼
lnð2Þ
1þ e H : ð54Þ
In terms of the original variables we thus obtain
A2ðtÞ ! A2 ¼ q
k20
y ¼ q







When H ¼ 100 and k20 ¼ 0:01, then A2 ¼ 50 q mg
and t1=2 ¼ 34:7 h (cf. Fig. 2).
A large time scale
We choose k1p h as a reference time and define the
dimensionless time s2 ¼ kp t. Putting this time variable into












Again, by standard singular perturbation theory (cf.
[7, 8, 10]) it follows that after a very short time
1 y e H  ðy zÞ ¼ 0 ¼) y ¼ 1þ e H  z
1þ e H
ð57Þ
Using this expression for y in the second equation of the




1þ e H ð58Þ
Remembering that zð0Þ ¼ 0, it follows that
zðs2Þ ¼ 1 ec s2 ; where c ¼ 1
1þ eH
and the half-life s2;1=2 in the second phase is given by
s2;1=2 ¼ ð1þ e HÞ lnð2Þ
¼) t1=2 ¼ 1
kp
ð1þ e HÞ lnð2Þ ð59Þ
and the terminal slope kz is given by
kz ¼ kp
1þ e H ð60Þ
Comparing the expressions (55) and (59) for the half-life
in, respectively, the first and the second phase, we see that
as the capacity increases, the half-life decreases in the first
phase and increases in the second phase.
If H ¼ 100, then t1=2 ¼ 1:4 104 h,which agrees with
the simulations in Fig. 2.
Appendix 2: mathematical analysis
of the nonlinear model
Here we define the dimensionless variables
x ¼ A1
A1;ss
; y ¼ A2
A2;ss
; z ¼ A3
Bmax
ð61Þ
in which for A1 and A2 we have chosen the same reference
values, whilst for A3 we have chosen the fixed capacity
Bmax which serves as a uniform bound for A3 (cf. (7)).
In addition we define the dimensionless constants
b ¼ Bmaxkp
q
and jM ¼ k20
q
KM ð62Þ





















As with the linear model, within a very short time xðtÞ  1
so that we may put xðtÞ ¼ 1 and reduce the system (63) to















A short time scale
As with the linear model we use the dimensionless time
s1 ¼ k20t. Introducing this variable into the system (63) and
setting x ¼ 1, we obtain the reduced system
dy
ds1
¼ 1 y b y













Since e 1 it follows that for s1 ¼ Oð1Þ, we may put




¼ f ðyÞ ¼def 1 y b y
jM þ y ð66Þ
Since f(y) is strictly decreasing, f ð0Þ ¼ 1 and f ð1Þ\0, it
follows that f(y) has a unique zero y between 0 and 1.
Plainly, y is one of the two roots of the quadratic equation
y2 þ ðbþ jM  1Þy jM ¼ 0 ð67Þ
One of these roots is negative and the other is positive.
Plainly y is the positive one which is given by
y ¼ 1
2
ð1 b jMÞ þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð1 b jMÞ2 þ 4jM
q 	
ð68Þ
Because yð0Þ ¼ 0 and f ðyÞ[ 0 for 0	 y\y, it follows
from (66) that
yðs1Þ ! y as s1 !1 ð69Þ
In order to determine the rate of convergence towards y we
linearise equation (66) at y. Writing y ¼ yþ g, we can
write equation (66) as
dg
ds1
¼ f ðyþ gÞ ¼ f 0ðyÞ gþ qðgÞ
where g1 qðgÞ as g! 0
ð70Þ
in which









¼ 1 b jMðjM þ yÞ2
ð71Þ
Omitting the small rest term qðgÞ we conclude that the
terminal slope is approximately given by
1þ b jMðjM þ yÞ2 ð72Þ
Returning to the original variables, this translates into (cf.
equation (25)):
kz ¼ k20 þ Bmax kp KMðKM þ A2Þ2 ð73Þ
A graph of the terminal slope in the first phase, as it varies
with q and Bmax, is shown in Fig. 6.
Example When q ¼ 5 we obtain for the parameter values
given by Table 1, that y ¼ 0:558, and hence A2 ¼ 279 mg,
and





which is consistent with what we observe in the simulation
shown in Fig. 3 for q ¼ 5.
A large time scale





¼ 1 y b y











On the basis of singular perturbation theory (cf. [7, 8, 10]),
we may put
1 y b y
jM þ y z
 
¼ 0 ð76Þ
which yields an expression for z in terms of y:





When we substitute this expression into the equation for z







or, when we divide by u0ðyÞ,
dy
ds2




The terminal slope (in terms of s2) is now given by





In terms of the original time t this translates into
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kzðqÞ ¼ kp 1þ Bmax kp KM k20ðqþ KM k20Þ2
 !1
ð81Þ
We conclude from this expression that the terminal slope
increases as the infusion rate increases, and that its limiting
values values are given by
kzðqÞ ! kp as q!1 ð82Þ
and





as q! 0 ð83Þ
A graph of the terminal slope in the second phase, as it
varies with q and Bmax, is shown in Fig. 4.
Appendix 3: mathematical analysis: small capacity
and rapid exchange
In Appendix 3 we focus on the small capacity - fast dis-
tribution case (cf. 47 and 48). Thus,
ka  kp  k20 ð84Þ
We introduce dimensionless variables using KM as a ref-




; y ¼ A2
KM
; z ¼ A3
KM
; s ¼ ka t: ð85Þ







¼ x ly be y
yþ 1þ ez b ¼
Bmax
KM
; e ¼ kp
ka














Note that for the parameter values of Table 2, used in
Fig. 4, we obtain b ¼ 10, e ¼ 0:2 and l ¼ 0:04.
In order to obtain a first estimate, we put l ¼ 0 and also
e ¼ 0, except when e is multiplied by b since the product
b e ¼ 2 is clearly not small. Solving the first equation we
obtain xðsÞ ¼ des with d ¼ D=KM . Substituting this
expression for xðsÞ into the second equation we obtain a
single equation for yðsÞ:
dy
ds
¼ des  be y
yþ 1 ð87Þ
When y 1 Eq. (87) may approximated by the equation
dy
ds
¼ des  bey ð88Þ




ðes  ebesÞ ðbe 6¼ 1Þ ð89Þ
An elementary computation shows that
ymax ¼ d
(
ðbeÞbe=ðbe1Þ if be 6¼ 1
e1 if be ¼ 1
ð90Þ
When y 1 we scale Eq. (87) and write y ¼ dz. The
resulting equation may then be approximated by
dz
ds
¼ es  be d1: ð91Þ
Its solution which starts at the origin is given by
zðsÞ ¼ 1 es  be
d
s ð92Þ
Returning to y, we then deduce that
ymax ¼d 1 bed
 
 be ln d
be
 






In terms of the original variables, the expressions (93) and
(93) yield the limits given in Eq. (39).
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